- Aclarion's Nociscan shows $1,712 in savings per patient over traditional methods.
- Study indicates a 10% improvement in surgical success rates with Nociscan.
- Nociscan uses biomarkers and AI to noninvasively identify painful discs in the lumbar spine.
Aclarion, Inc. (ACON, Financial) has announced the publication of a peer-reviewed cost-effectiveness analysis of its Nociscan technology in the Clinicoeconomics and Outcomes Research journal. The study demonstrates that Nociscan, a SaaS platform aimed at identifying chronic low back pain locations, is more cost-effective by saving $1,712 per patient compared to traditional provocative discography.
Nociscan leverages biomarkers and advanced AI algorithms to help physicians noninvasively distinguish between painful and nonpainful discs in the lumbar spine. This advantage addresses an immense healthcare challenge affecting approximately 266 million people worldwide suffering from degenerative spine disease and chronic low back pain.
The technology not only reduces costs but also improves surgical success rates by 10%, providing significant value in today’s cost-conscious healthcare environment. The economic and clinical benefits presented in this peer-reviewed study are expected to resonate positively with both healthcare providers and payers.
